文献速递慢性肾脏病

美国CKD患者他汀类药物一级预防的使用趋势

Use of Statins for Primary Prevention Among Individuals With CKD in the United States: A Cross-Sectional, Time-Trend Analysis.
PubMed 文献 · Am J Kidney Dis · 2024-12-31

该研究基于2001-2020年NHANES数据,纳入符合2013年KDIGO指南他汀一级预防标准的CKD患者,分析他汀使用的时间趋势。结果显示他汀使用率从2001-2002年的18.6%升至2007-2008年的36.1%,2013-2014年小幅增至40.1%后趋于平稳;多因素分析显示有保险、高血压和糖尿病患者使用率更高,低eGFR和高BMI者也更常见。

要点

  • 符合KDIGO标准的CKD患者他汀一级预防使用率从18.6%升至40.1%后平台。
  • 有保险者使用率是无保险者的2.48倍(PR 2.48,95%CI 1.66-3.69)。
  • 高血压和糖尿病患者他汀使用率更高(PR分别为1.49和1.71)。

核心结论

  • CKD患者他汀一级预防使用率在2013年KDIGO指南发布前已大幅上升,之后趋于平稳,仍有近半数合格者未用药。
  • 有保险、高血压或糖尿病的患者他汀使用率更高。

研究设计与样本

  • 横断面时间趋势分析,使用2001-2020年NHANES数据。
  • 纳入年龄≥50岁、无自报CVD、eGFR<60mL/min/1.73m2或UACR≥30mg/g、且过去12个月未透析的CKD患者。

主要发现

  • 合格患者他汀使用率从2001-2002年的18.6%升至2007-2008年的36.1%,2013-2014年增至40.1%后趋于平稳。
  • 多因素分析显示有保险者使用率更高(PR 2.48,95%CI 1.66-3.69)。
  • 高血压患者使用率更高(PR 1.49,95%CI 1.28-1.74),糖尿病患者更高(PR 1.71,95%CI 1.52-1.92)。
  • eGFR越低他汀使用越常见(P=0.009),BMI越高使用越常见(P=0.003)。
  • 他汀使用率在性别、种族或族裔间无差异。

关键数值与推荐

  • 2013年KDIGO指南推荐对年龄≥50岁、无CVD的CKD患者使用他汀进行一级预防。

临床怎么用

  • 应关注CKD患者他汀一级预防的未充分使用,尤其无保险者。
  • 高血压和糖尿病共存时应强化他汀一级预防评估。

局限性

  • 他汀使用和CVD均为自报,未捕获他汀不耐受及医患决策信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Chronic kidney disease (CKD) populations face an elevated risk of cardiovascular disease (CVD), yet many remain undertreated with statins for primary prevention of CVD despite meeting eligibility criteria. We examined trends in statin use for primary prevention among individuals with CKD before and after the release of the 2013 Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommending statin use for lipid management in selected adults with CKD. STUDY DESIGN: Cross-sectional time-trend analysis. SETTING & PARTICIPANTS: The 2001-2020 National Health and Nutrition Examination Survey (NHANES) data permitted identification of individuals eligible for statin therapy per the 2013 KDIGO guidelines based on (1) age≥50 without self-reported CVD; (2) CKD, defined as estimated glomerular filtration rate (eGFR)<60mL/min/1.73m2 or albumin-creatinine ratio≥30mg/g; and (3) no dialysis in the previous 12 months. OUTCOME: Statin use. ANALYTICAL APPROACH: Poisson regression to estimate prevalence ratios (PR) comparing the periods before and after KDIGO guideline release and after accounting for NHANES's complex survey design and sampling weights. RESULTS: Among eligible individuals, statin use approximately doubled from 18.6% in 2001-2002 to 36.1% in 2007-2008, increased modestly to 40.1% in 2013-2014, then subsequently plateaued. Multivariable analyses controlling for sociodemographic and clinical characteristics and secular trends demonstrated statin use for primary prevention was higher among the insured (PR, 2.48 [95% CI 1.66-3.69]), those with hypertension (PR, 1.49 [95% CI 1.28-1.74]), and those with diabetes (PR, 1.71 [95% CI 1.52-1.92]). Statin use was more common with lower eGFR (P=0.009) and higher body mass index (P=0.003) but did not differ by sex, race, or ethnicity. LIMITATIONS: Statin use and CVD were self-reported, and our data did not capture statin intolerance nor patient-provider decision making information. CONCLUSIONS: Statin use for primary prevention in CKD substantially increased before the 2013 release of KDIGO guidelines and subsequently plateaued. Use was higher among the insured and those with hypertension or diabetes. PLAIN-LANGUAGE SUMMARY: Chronic kidney disease (CKD) affects many Americans, increasing their heart disease risk. Statins effectively reduce this risk in individuals with CKD but are underused. Our study examined statin use in individuals with CKD before and after the release of the 2013 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommending statin use for selected adults with CKD. It also examined factors influencing usage patterns. Using years of US National Health and Nutrition Examination Survey data, we found that while statin use doubled over the study period, fewer than half of eligible individuals with CKD received statins for primary prevention. Statin use was more common among those with health insurance, high blood pressure, or diabetes. This underuse highlights potential opportunities for improved risk monitoring and preventive use of statin therapy for individuals with CKD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Iyalomhe OE, Saparamadu AADNS, Alexander GC, et al. Use of Statins for Primary Prevention Among Individuals With CKD in the United States: A Cross-Sectional, Time-Trend Analysis. Am J Kidney Dis. 2024. PMID: 39743168. doi:10.1053/j.ajkd.2024.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。